合成MRI影像组学预测HER2阳性乳腺癌新辅助治疗pCR的增量价值
回顾性纳入三中心404例HER2阳性乳腺癌患者,构建整合拓扑与Hessian特征的合成影像组学模型(S-Radiomics)并验证其预测病理完全缓解的能力。S-Radiomics在内部与外部测试集AUC分别为0.86和0.84,均优于传统影像组学模型。拓扑特征被Shapley分析判定为最重要的预测因子。
要点
- S-Radiomics预测pCR的AUC在内部测试集为0.86,外部测试集为0.84。
- 拓扑特征是最重要的预测因子,阅片时可重点关注肿瘤内部结构复杂性。
- 预测为应答者的患者无病生存期更长(中心1,P = .02)。
核心结论
- S-Radiomics在预测HER2阳性乳腺癌患者病理完全缓解方面优于传统影像组学模型。
- 在外部测试集中,S-Radiomics相较于传统影像组学模型在净重新分类指数上具有统计学显著改善(P = .01)。
研究设计与样本
- 研究类型为回顾性多中心研究,纳入2018年1月至2024年1月三个中心的404例HER2阳性乳腺癌女性患者。
- 中心1和中心2共201例患者随机分为训练集150例和内部测试集51例,中心3的82例构成外部测试集I。
- 额外使用I-SPY 2基因组集64例和I-SPY 1外部测试集II 57例进行独立验证。
- 采用多变量logistic回归筛选独立预测因子(P < .05)并构建临床模型,同时校正潜在混杂因素。
关键影像表现/征象
- 拓扑特征在Shapley加性解释分析中被判定为最重要的预测因子。
- S-Radiomics整合了拓扑特征、Hessian特征与传统影像组学特征。
诊断标准与关键数值
- 内部测试集:S-Radiomics的AUC为0.86,传统影像组学模型为0.78,P = .37。
- 外部测试集:S-Radiomics的AUC为0.84,传统影像组学模型为0.73,P = .11。
- 综合判别改善指数在内部测试集P = .24,外部测试集P = .01。
- 净重新分类指数在内部测试集P = .21,外部测试集P = .01。
临床应用与阅片要点
- 拓扑特征作为最重要预测因子,提示阅片时应重视肿瘤内部空间结构与连接性的评估。
- S-Radiomics在外部验证中展现出良好的预测稳定性,支持跨中心应用的潜力。
- 预测为应答者的患者无病生存期更长,影像组学预测结果对预后判断有参考价值。
局限性
- 研究为回顾性设计,存在选择偏倚的可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To evaluate the added value of a synthetic radiomics model (S-Radiomics) that integrates topologic and Hessian-based features with traditional radiomic features for predicting a pathologic complete response (pCR) in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Materials and Methods Patients with HER2-positive breast cancer from three centers were retrospectively included between January 2018 and January 2024. Patients from centers 1 and 2 (n = 201) were randomly assigned to training (n = 150) and internal testing (n = 51) sets, whereas patients from center 3 (n = 82) constituted external testing set I. An additional genomic set (n = 64, I-SPY 2) and external testing set II (n = 57, I-SPY 1) were used for independent validation. Multivariable logistic regression with all clinical variables was used to identify independent predictors (P < .05) and develop the clinical model, adjusting for potential confounders. Traditional radiomics model (T-Radiomics) and S-Radiomics were constructed. Performance was evaluated using area under the receiver operating characteristic curve (AUC), integrated discrimination improvement, net reclassification index, and survival analysis. Results A total of 404 female patients with HER2-positive breast cancer (mean age ± SD, 50 years ± 9) were included. The S-Radiomics outperformed the T-Radiomics on both the internal (AUC, 0.86 vs 0.78; P = .37) and external test (AUC, 0.84 vs 0.73; P = .11) sets, with improvements in the integrated discrimination improvement (P = .24 and .01) and net reclassification index (P = .21 and .01). Shapley additive explanations analysis revealed topologic features as the most important predictors. For center 1, survival analysis revealed longer disease-free survival in predicted responders (P = .02). Conclusion The S-Radiomics outperformed the T-Radiomics in predicting pathologic complete responses in patients with HER2-positive breast cancer. Keywords: Radiogenomics, MRI, Breast, Human Epidermal Growth Factor Receptor 2, Breast Cancer, Neoadjuvant Chemotherapy, Pathologic Complete Response, Radiomics Supplemental material is available for this article. © RSNA, 2026.
引用
- Chen, Chen, Jin, et al. Incremental Value of Synthetic MRI Radiomics in Predicting Neoadjuvant Response in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Radiol Imaging Cancer. 2026. PMID: 42599169. doi:10.1148/rycan.250758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。